Phase 1 N=16 Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections
Diabetes · Wound Infection · Healthy Volunteers
Primary: Ceftolozane Tissue Penetration — 0.75; 0.87 ratio
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=24 Drug-Drug Interaction Study: ASP2151 and Bupropion
Healthy
Primary: Peak Plasma Concentration (Cmax) of Bupropion — 91.28; 76.94; 92.21; 95 ng/mL
Phase 1 N=10 A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants
Healthy Participants
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-954 — 2.642; 2.840 nanogram/milliliter (ng/mL)
Phase 1 N=18 Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis
Diabetes · Wound Infection · Healthy Volunteers
Primary: Tedizolid Tissue Penetration — 0.98; 0.82 ratio
Phase 1 N=103 Study of Erenumab (AMG 334) in Women With Hot Flashes
Vasomotor Symptoms; Hot Flashes
Primary: Ratio of Week 4 to Baseline Average Number of Daily Moderate to Severe Hot Flashes — 0.35; 0.38 ratio — p=0.723
Phase 1 N=24 Drug-Drug Interaction Study: ASP2151 and Montelukast
Healthy
Primary: Peak Plasma Concentration (Cmax) of Montelukast — 415.6; 505.9 ng/mL
Phase 1 N=12 Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects
Pulmonary Disease, Chronic Obstructive
Primary: Mean GSK2269557 Plasma Concentration — 0.0; 0.0; 2175.5; 1871.8 Picograms per milliliter
Phase 1 N=27 Drug-Drug Interaction Study: ASP2151 and Midazolam
Healthy
Primary: Peak Plasma Concentration (Cmax) of Midazolam — 34.5; 23.4; 38.8; 36.8 ng/mL
Phase 1 N=37 A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects
Schizophrenia
Primary: Lurasidone Cmax — 32.9; 50.9; 113 ng/ml
Phase 1 N=48 Drug-Drug Interaction Study: ASP2151 and Ritonavir
Healthy
Primary: Peak Plasma Concentration (Cmax) of ASP2151 — 1845.7; 2518.7; 3804; 6211.6 ng/mL
Phase 1 N=12 A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants
Healthy Participants
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-906 — 9.532; 17.999 nanogram per milliliter (ng/mL)
Phase 1 N=39 Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Advanced or Recurrent Solid Tumors · Breast Neoplasms · Ovarian Cancer, Epithelial
Primary: Number of Participants With Objective Response — 8; 12; 2; 0 participants
Phase 1 N=160 Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects
Healthy
Primary: AUC0-tz of Free Dabigatran — 725.03686; 668.42714 Nanogram*hour/milliliter (ng･h/mL)
Phase 1 N=51 Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Part A Cmax: Maximum Observed Plasma Concentration for MLN4924 and MLN4924 + Fluconazole — 51.6; 51.0 nanogram per milliliter (ng/mL)
Phase 1 N=120 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers
Healthy Volunteers
Primary: Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) in Part 1 Single-rising Dose (SRD) — 11.1; 0; 0; 16.7 percentage of…